-
Leukemia & Lymphoma Aug 1997Despite lack of cross-resistance with vincristine and a somewhat different toxicity spectrum, the semi-synthetic vinca alkaloid, vindesine, has not yet achieved its... (Review)
Review
Despite lack of cross-resistance with vincristine and a somewhat different toxicity spectrum, the semi-synthetic vinca alkaloid, vindesine, has not yet achieved its expected potential in the treatment of acute leukaemias. The ability of vindesine to induce remissions in vincristine-resistant and relapsed ALL is of particular interest for the development of potentially curative second-line regimens. Vindesine may also have a role in consolidation strategies for de novo ALL, although it will be difficult to demonstrate specific advantages for this agent as part of a multidrug treatment approach. In myeloid leukaemias, while vindesine appears to have a limited role in ANLL, it may be useful for the palliative treatment of CML blast crisis. In the future, new synergistic combinations, incorporating vindesine with for example, methotrexate or edatrexate, may be developed.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vindesine
PubMed: 9389357
DOI: 10.3109/10428199709050886 -
Nursing Mar 2009
Topics: Adult; Antineoplastic Agents, Phytogenic; Female; Humans; Vindesine
PubMed: 19247102
DOI: 10.1097/01.NURSE.0000347050.21740.8c -
Investigational New Drugs 1993Vindesine is a semisynthetic derivative of vinblastine which has been evaluated in clinical studies since the late 1970's. The literature on vindesine in the treatment... (Comparative Study)
Comparative Study Review
Vindesine is a semisynthetic derivative of vinblastine which has been evaluated in clinical studies since the late 1970's. The literature on vindesine in the treatment of non-small cell lung cancer has been reviewed and all aspects of vindesine treatment in this disease has been covered. It is concluded that vindesine as a single agent yields a response rate of 18% based on the treatment of 295 patients included in phase II trials (95% confidence limits 13%-22%). No difference was observed among the three major histologic types of non-small cell lung cancer. In phase III trials, the response rate and confidence limits are at a similar level. Combination chemotherapy including vindesine plus cisplatin ranks among the most active treatments in non-small cell lung cancer and is as active as etoposide plus cisplatin, both with respect to response rate and survival. It has not been documented that the addition of one or two other drugs to the combination of vindesine yields an increase in survival. When best supportive care was compared with a combination of vindesine plus cisplatin, the group with chemotherapy was attributed a survival advantage in all three studies published, and the difference was statistically significant in two of these three studies. Thus, vindesine has a well documented activity in non-small cell lung cancer and ranks among the most active single agents in this disease. Vindesine is also part of several active combination chemotherapies among which the combination of vindesine plus cisplatin is particularly interesting, because it has been repeatedly shown to prolong survival as compared to supportive care. Especially this latter point leads to the conclusion that there is a role for vindesine in the treatment of non-small cell lung cancer. However, the concept of chemotherapy in this disease remains investigational even though the advances seen in recent years clearly merit further studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Vindesine
PubMed: 8262725
DOI: 10.1007/BF00874146 -
Lancet (London, England) Apr 1981
Topics: Aged; Humans; Male; Psoriasis; Vinblastine; Vindesine
PubMed: 6110967
DOI: 10.1016/s0140-6736(81)92639-8 -
Journal of Cancer Research and Clinical... Jan 1998Locally advanced non-small-cell lung cancer (NSCLC) in most cases is not curable at the present time. Owing to the local extent of the tumor, the rate of complete... (Review)
Review
Locally advanced non-small-cell lung cancer (NSCLC) in most cases is not curable at the present time. Owing to the local extent of the tumor, the rate of complete resections is low and, therefore, survival in these patients is poor. For this reason, induction chemotherapy is being investigated in patients expected to have a poor prognosis after standard surgery and radiotherapy. The rationale for induction chemotherapy is to increase the rate of complete resections and achieve early elimination of micrometastases. Clinical investigations have reported an improvement of survival in stage III NSCLC after induction chemotherapy by using different combinations of cytotoxic drugs. Vindesine ranks among the most active single agents in this disease and has been part of a number of combination regimens in induction chemotherapy. The combination of mitomycin, vindesine or vinblastine and cisplatin has produced encouraging results in several studies, indicating a possible improvement of survival in stage III NSCLC, although its superiority to other combinations yet has to be demonstrated.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Vindesine
PubMed: 9498828
DOI: 10.1007/s004320050126 -
Anti-cancer Drugs Oct 1995Vindesine, a vinca alkaloid derived from vinblastine, has been examined for activity against a variety of solid and hematological malignancies. Single-agent response... (Review)
Review
Vindesine, a vinca alkaloid derived from vinblastine, has been examined for activity against a variety of solid and hematological malignancies. Single-agent response rates average 18% in non-small cell lung cancer and it has been widely used in combination with cisplatin as first-line therapy for this disease. It has limited activity in breast cancer (average 16% response rate) and does not appear to improve outcome when combined with anthracyclines. Vindesine is frequently incorporated into combination regimens for the treatment of malignant melanoma, and head and neck cancer, although its single-agent activity in these diseases is modest (average 14 and 12% response rates, respectively). Its activity in the hematological malignancies appears to be greater and it has an important role in the treatment of acute lymphoblastic leukemia, particularly in children. It is currently being examined for its potential to synergize with the interferons and for its value as prolonged therapy in preventing metastasis.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Humans; Leukemia; Lung Neoplasms; Lymphoma; Melanoma; Vindesine
PubMed: 8845472
DOI: 10.1097/00001813-199510000-00001 -
Leukemia & Lymphoma Oct 2021
Topics: Aged; Dendritic Cells; Dexamethasone; Hematologic Neoplasms; Humans; Myeloproliferative Disorders; Skin Neoplasms; Vindesine
PubMed: 33904349
DOI: 10.1080/10428194.2021.1919664 -
Cancer Apr 1990The current trial was carried out to assess the survival enhancement achieved, if any, by adding ifosfamide to vindesine and cisplatin (IVP) in contrast to mitomycin... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial Review
A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
The current trial was carried out to assess the survival enhancement achieved, if any, by adding ifosfamide to vindesine and cisplatin (IVP) in contrast to mitomycin plus vindesine and cisplatin (MVP). Between June 1986 and September 1988, 110 patients were randomly allocated to receive either ifosfamide (3 g/m2 plus 3 g/m2 of mesna) or mitomycin 8 mg/m2, on days 1, 29, and 71 only. In both arms vindesine was given 3 mg/m2 weekly X 5 then every 2 weeks. In the MVP arm, 120 mg/m2 of cisplatin was administered on days 1 and 29 and then every 6 weeks, whereas in the IVP arm 100 mg/m2 of cisplatin was given on the same time schedule. One hundred three patients were evaluable for response and toxicity and 56% of patients had Mountain's Stage IV disease. The response rate was 26% (14/53 patients) in the MVP arm (95% confidence interval, 14%-39%) and 20% (ten of 50 patients) in the IVP arm (95% confidence interval, 10%-34%). Neither the response rate nor the median survival times were significantly different, although more nephrotoxicity was produced in the MVP arm, grade 1+ in 43% versus 26% in IVP arm (P = 0.04). Results obtained from this study fail to demonstrate that mitomycin or ifosfamide have a synergistic effect on the efficacy of the vindesine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Female; Humans; Ifosfamide; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Random Allocation; Remission Induction; Survival Rate; Vindesine
PubMed: 2156597
DOI: 10.1002/1097-0142(19900415)65:8<1692::aid-cncr2820650805>3.0.co;2-x -
Journal of Clinical Oncology : Official... Aug 2010This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to compare third-generation chemotherapy with second-generation chemotherapy in patients... (Comparative Study)
Comparative Study Randomized Controlled Trial
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
PURPOSE
This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to compare third-generation chemotherapy with second-generation chemotherapy in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
PATIENTS AND METHODS
Eligible patients received the following treatments: A (control), four cycles of mitomycin (8 mg/m(2) on day 1)/vindesine (3 mg/m(2) on days 1, 8)/cisplatin (80 mg/m(2) on day 1) plus TRT 60 Gy (treatment break for 1 week); B, weekly irinotecan (20 mg/m(2))/carboplatin (area under the plasma concentration-time curve [AUC] 2) for 6 weeks plus TRT 60 Gy, followed by two courses of irinotecan (50 mg/m(2) on days 1, 8)/carboplatin (AUC 5 on day 1); C, weekly paclitaxel (40 mg/m(2))/carboplatin (AUC 2) for 6 weeks plus TRT 60 Gy, followed by two courses of paclitaxel (200 mg/m(2) on day 1)/carboplatin (AUC 5 on day 1).
RESULTS
The median survival time and 5-year survival rates were 20.5, 19.8, and 22.0 months and 17.5%, 17.8%, and 19.8% in arms A, B, and C, respectively. Although no significant differences in overall survival were apparent among the treatment arms, noninferiority of the experimental arms was not achieved. The incidences of grade 3 to 4 neutropenia, febrile neutropenia, and gastrointestinal disorder were significantly higher in arm A than in arm B or C (P < .001). Chemotherapy interruptions were more common in arm B than in arm A or C.
CONCLUSION
Arm C was equally efficacious and exhibited a more favorable toxicity profile among three arms. Arm C should be considered a standard regimen in the management of locally advanced unresectable NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Radiotherapy, Adjuvant; Vindesine
PubMed: 20625120
DOI: 10.1200/JCO.2009.24.5050 -
Leukemia Research Dec 2009A 13-year-old girl with acute lymphoblastic leukaemia, who was being treated with chemotherapy (including vindesine), developed paraplegia without paresthesia, which...
A 13-year-old girl with acute lymphoblastic leukaemia, who was being treated with chemotherapy (including vindesine), developed paraplegia without paresthesia, which mimic Guillain-Barré syndrome. Spinal fluid analysis showed a normal protein level, vindesine neuropathy seemed to be the cause of the patient's neurological symptoms. The patient seemed to benefit from human normal immunoglobulin therapy and recovered 4 weeks later.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Diagnosis, Differential; Female; Guillain-Barre Syndrome; Humans; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vindesine
PubMed: 19428104
DOI: 10.1016/j.leukres.2009.04.014